Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

作者：Jour George; Glitza Isabella C; Ellis Rachel M; Torres Cabala Carlos A; Tetzlaff Michael T; Li Janet Y; Nagarajan Priyadharsini; Huen Auris; Aung Phyu P; Ivan Doina; Drucker Carol R; Prieto Victor G; Rapini Ronald P; Patel Anisha; Curry Jonathan L^*

来源：Journal of Cutaneous Pathology, 2016, 43(8): 688-696.

DOI：10.1111/cup.12717

• anti-PD-1 antibody
• autoimmune dermatologic toxicities
• bullous erythema multiforme
• bullous pemphigoid

Monoclonal antibodies against the immune checkpoint programmed cell death receptor 1 (PD-1) improve the hosts' antitumor immune response and have showed tremendous promise in the treatment of advanced solid tumors and hematologic malignancies. Reports of serious autoimmune dermatologic toxicities from immune checkpoint blockade therapy, however, are emerging. We report our experience with five patients who presented with pruritic vesicles and blisters on the skin while treated with anti-PD-1 antibody immunotherapy with either nivolumab or pembrolizumab. Four of the patients' skin biopsies revealed subepidermal bullae with immunohistochemical study for type IV collagen labeling the floor of the blister cavity and direct immunofluorescence studies (in three of the four patients tested) decorated linear IgG and C3 immune deposits on the blister roof, diagnostic of bullous pemphigoid. One patient developed bullous erythema multiforme. All patients had partial or complete resolution of skin lesions following treatment with systemic corticosteroid and cessation of checkpoint blockade. Recognition and treatment of rare immune-related bullous dermatologic toxicities will become increasingly important as more patients are treated with effective and newer immune checkpoint blockade therapy.

• 出版日期2016-8